Streamline T cell activation in your research workflows with T Cell TransAct™

Our research-grade T Cell TransAct is ready-to-use for in vitro activation and expansion of human T cells. T Cell TransAct is a colloidal polymeric nanomatrix conjugated to humanized recombinant CD3 and CD28 agonists. Its polymeric nanomatrix structure ensures gentle and efficient activation of resting T cells from PBMCs and of enriched T cell populations while maintaining high viability.

Watch the video to learn how T Cell TransAct can optimize T cell research

  • Save time and money
  • Quick and easy protocol
  • Removal by simple washing - no magnet needed, no bead removal
  • Convenient, ready-to-use reagent

Key benefits of T Cell TransAct

T cell activation by T Cell TransAct, measured by CD25/CD69 expression.

Robust stimulation and expansion of T cells

Highly efficient T cell stimulation results in safe, easy, and reliable research.

After two days, T Cell TransAct activates over 80% of T cells, as indicated in the graph with CD25 and CD69 markers. Its polymeric nanomatrix ensures optimal activation and supports robust serum-free T cell growth for reliable, high-level proliferation.

T cell expansion after stimulation with T Cell TransAct compared to a bead based product.

Consistent T cell expansion and survial in serum-free conditions

Excellent T cell growth is observed after stimulation with T Cell TransAct in serum-free culture conditions.

The graph shows cell stimulation with T Cell TransAct used with serum-free TexMACS™ Medium and Human IL-2 IS. T cell expansion remained consistently high after two weeks (red line), and demonstrated comparable performance to a competing bead-based product (grey line). The synergistic combination of T Cell TransAct, TexMACS Medium and MACS® Cytokines ensures an optimal cell product independent of serum addition.

Strong activation in both CD4+ and CD8+ cells after the addition of T Cell TransAct.

Strong polyclonal T cell activation

T Cell TransAct allows for potent polyclonal T cell activation.

Human purified T cells were activated for 48 hours using T Cell TransAct in TexMACS Medium supplemented with Human IL-2. A negative control was conducted without the addition of T Cell TransAct. Flow cytometry analysis showed activation in both CD4+ and CD8+ cells after the addition of T Cell TransAct, as indicated by CD25/69 expression.

Applications - from research to clinical

Workflow for CAR T cell engineering.

Highlight application: Engineered T cells for research

T cells activated with T Cell TransAct can be used for applications such as CAR (Chimeric Antigen Receptor) T cell research.

See our complete research workflow for engineered T cells

Translatability of T Cell TransAct for T cell activation process development.

Clinical translation made easy

Simplifying the transition from research to clinical applications using MACS® GMP T Cell TransAct™. Our reageants are designed to deliver consistent results.

Highlight references for research applications

CAR T cell generation and functional validation of newly identified CAR T cell targets.
Schäfer, D. et al. (2021) Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nature Communications 12: 1453. https://doi.org/10.1038/s41467-021-21774-4

Establishment of a novel humanized artificial receptor platform termed RevCARs for CAR T cell optimization. Pan T cell activation using T Cell TransAct.
Feldmann, A. et al. (2020) Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology 9: 1785608. https://doi: 10.1080/2162402X.2020.1785608

Investigation of iPSC-derived T cell functionality (cell proliferation and expression of activation marker) by responding to T Cell TransAct-mediated TCR activation.
Netsrithong, R. et al. (2020) Multilineage differentiation potential of hematoendothelial progenitors derived from human induced pluripotent stem cells. Stem Cell Research & Therapy 11: 481. https://doi.org/10.1186/s13287-020-01997-w

Engineering of an affinity-matured human antibody that mediates antibody dependent cellular cytotoxicity of mutant p53 expressing cells in vitro.
Low, L. et al. (2019) Targeting mutant p53-expressing tumours with a T cell receptor–like antibody specific for a wild-type antigen. Nat. Commun. 10: 5382. https://doi.org/10.1038/s41467-019-13305-z

T Cell TransAct™

Available in two fill sizes:

  • T Cell TransAct™ 1x 2 ml: Optimized to expand 2×108 enriched T cells.
  • T Cell TransAct™ 2x 2 ml: Optimized to expand 4×108 enriched T cells.

1 product found

|